Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaRoshani Patel, Elizabeth Hill, Amrit Bhaskarla et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0